阿达格拉西布在 NSCLC 中的应答仍然强劲。
Adagrasib Response Remains Strong in NSCLC.
出版信息
Cancer Discov. 2022 Aug 5;12(8):OF1. doi: 10.1158/2159-8290.CD-NB2022-0042.
Abstract
In the phase II KRYSTAL-1 trial, the KRASG12C inhibitor adagrasib yielded an overall response rate of 43% and a disease control rate of 80% in patients with previously treated KRASG12C-mutant non-small cell lung cancer. After a median follow up of 12.9 months, overall survival was 11.7 months. The drug also shrank brain metastases in 33% of patients who had them.
摘要
在 II 期 KRYSTAL-1 试验中，先前接受治疗的 KRASG12C 突变型非小细胞肺癌患者中，KRASG12C 抑制剂 adagrasib 的总体缓解率为 43%，疾病控制率为 80%。中位随访 12.9 个月后，总生存期为 11.7 个月。该药还使 33%有脑转移的患者的脑转移缩小。
Zotero 插件